Cartesian Therapeutics (RNAC) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $4.1 million.
- Cartesian Therapeutics' Accumulated Depreciation & Amortization fell 3467.45% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 3467.45%. This contributed to the annual value of $2.4 million for FY2024, which is 5885.13% down from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Accumulated Depreciation & Amortization is $4.1 million, which was down 3467.45% from $3.5 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Accumulated Depreciation & Amortization registered a high of $6.3 million during Q3 2024, and its lowest value of $2.4 million during Q4 2024.
- For the 5-year period, Cartesian Therapeutics' Accumulated Depreciation & Amortization averaged around $4.8 million, with its median value being $4.8 million (2022).
- As far as peak fluctuations go, Cartesian Therapeutics' Accumulated Depreciation & Amortization surged by 1568.33% in 2023, and later crashed by 5885.13% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $4.8 million in 2021, then grew by 8.51% to $5.2 million in 2022, then rose by 10.05% to $5.7 million in 2023, then tumbled by 58.85% to $2.4 million in 2024, then soared by 74.97% to $4.1 million in 2025.
- Its last three reported values are $4.1 million in Q3 2025, $3.5 million for Q2 2025, and $2.9 million during Q1 2025.